Research and Development Investment: Geron Corporation vs Galapagos NV

Biotech R&D: Galapagos vs. Geron - A Decade of Investment

__timestamp	Galapagos NV	Geron Corporation
Wednesday, January 1, 2014	111110000	20707000
Thursday, January 1, 2015	129714000	17831000
Friday, January 1, 2016	139574000	18047000
Sunday, January 1, 2017	218502000	11033000
Monday, January 1, 2018	322876000	13432000
Tuesday, January 1, 2019	427320000	52072000
Wednesday, January 1, 2020	523667000	51488000
Friday, January 1, 2021	491707000	85727000
Saturday, January 1, 2022	515083000	95518000
Sunday, January 1, 2023	241294000	125046000

Unleashing insights

A Decade of Innovation: R&D Investments in Biotech

In the ever-evolving world of biotechnology, research and development (R&D) investments are the lifeblood of innovation. Over the past decade, Galapagos NV and Geron Corporation have demonstrated contrasting strategies in their R&D expenditures.

Galapagos NV: A Steady Climb

From 2014 to 2023, Galapagos NV has consistently increased its R&D spending, peaking in 2020 with a remarkable 370% increase from 2014. This upward trend underscores the company's commitment to pioneering new treatments and therapies.

Geron Corporation: A Strategic Approach

Conversely, Geron Corporation's R&D investments have been more volatile, with a notable surge in 2023, marking a 500% increase from 2014. This strategic shift suggests a renewed focus on advancing their pipeline.

As these companies navigate the competitive biotech landscape, their R&D investments will continue to shape the future of medical breakthroughs.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025